Search Results
Your search for ,New matches 16912 pages
Showing 11351 - 11400Olanzapine Combination Reduces Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
In a phase III trial reported by Navari et al in The New England Journal of Medicine, the addition of the antipsychotic agent olanzapine vs placebo to dexamethasone, aprepitant, or fosaprepitant, and a 5-hydroxytryptamine type 3–receptor antagonist reduced nausea and improved antiemetic...
The National Cancer Moonshot Lifts Off
Just 6 months after President Barack Obama announced the establishment of a National Cancer Moonshot Initiative to accelerate the pace of research discoveries, improve patient access and care, and encourage data-sharing, dozens of new initiatives to accomplish those and other goals were rolled out...
Ipilimumab Appears Active in Relapsed Hematologic Cancer After Allogeneic HSCT
In a phase I/Ib study reported in The New England Journal of Medicine, Davids et al found that ipilimumab (Yervoy; at a dose of 10 mg/kg) produced responses, including complete responses, in patients with relapsed hematologic cancer after allogeneic hematopoietic stem cell transplantation (HSCT)....
Revisiting Ovarian Ablation in Early Breast Cancer: A Mismatch Between Global Values and Clinical Practice Guidelines
ASCO recently released a clinical practice guideline update on ovarian suppression as part of the extant guideline on adjuvant endocrine therapy in hormone receptor–positive breast cancer, and the recommendations were summarized in the June 10, 2016, issue of The ASCO Post. Also in this issue,...
NCCN Publishes New Patient Education Resources About Myelodysplastic Syndromes
To provide insight on myelodysplastic syndromes (MDS) for patients and caregivers, the National Comprehensive Cancer Network® (NCCN®) has published the NCCN Guidelines for Patients® and NCCN Quick Guide™ for MDS. These resources are provided through funding from the NCCN Foundation® and, in part,...
Study Finds Poor Understanding of Illness in Patients With Advanced Cancer
Few patients with advanced cancer and a short life expectancy have an accurate understanding of their illness, according to a study reported in the Journal of Clinical Oncology by Andrew S. Epstein, MD, of the Memorial Sloan Kettering Cancer Center, New York, and colleagues. The study involved 178...
Genomic Classification and Outcome in Acute Myeloid Leukemia
As reported in The New England Journal of Medicine, Elli Papaemmanuil, PhD, of the Cancer Genome Project, Wellcome Trust Sanger Institute, and colleagues have identified 11 genomic subgroups in acute myeloid leukemia (AML) associated with distinct diagnostic features and clinical outcomes. AML...
University of Kansas School of Medicine Names Allen M. Chen, MD, Department of Radiation Oncology Chair
Allen M. Chen, MD, has been appointed the new Joe and Jean Brandmeyer Chair of the Department of Radiation Oncology at the University of Kansas School of Medicine. He will join the faculty on October 1, 2016. Dr. Chen will succeed Terry Tsue, MD, the Douglas A. Girod, MD, Endowed Professor of Head ...
David Bartels, DO, Joins Summit Cancer Center–Post Falls
David Bartels, DO, will be joining Summit Cancer Center–Post Falls as a medical oncologist effective August 1, 2016, leaving his current position as a medical oncologist with Kootenai Health in Coeur d’Alene, Idaho. Summit Cancer Centers, associated with the Seattle Cancer Care Alliance, now...
Rajesh K. Garg, MD, JD, Named President, CEO of CTCA
Rajesh K. Garg, MD, JD, is now President and CEO of Cancer Treatment Centers of America Global, Inc (CTCA). The announcement was made by CTCA earlier this spring. Dr. Garg, who started this new position on June 20, 2016, will also serve as a member of the company’s national Board of Directors. Dr. ...
Dean Lee, MD, PhD, to Lead Cell Therapy Programs at Nationwide Childrens and OSUCCC–James
Dean Lee, MD, PhD, has been named the Director of the Cellular Therapy and Cancer Immunotherapy Program for Nationwide Children’s Hospital’s Division of Hematology/Oncology/Blood and Marrow Transplant and Center for Childhood Cancer and Blood Diseases. Dr. Lee will also serve as the Director of...
The Healing Power of Words
Feminist literary scholar Susan Gubar was diagnosed with advanced ovarian cancer in November 2008. She then began her emigration “from the world of the healthy to the domain of the ill,” she wrote in her acclaimed book, Memoir of a Debulked Woman: Enduring Ovarian Cancer. In her memoir, she...
An Epic Medical Story by an Old-Style Doctor on the Front Lines of Care
The U.S. health-care system is a $3 trillion behemoth of dizzying complexity. Government oversight, ever-changing regulations, mountains of paperwork, electronic health records, initiative after initiative, and so forth, all of which has reshaped the delivery of care, for the good and bad. But...
FDA Advances Precision Medicine Initiative by Issuing Draft Guidances on Next-Generation Sequencing–Based Tests
In support of the President’s Precision Medicine Initiative, on July 6, the U.S. Food and Drug Administration (FDA) issued two draft guidances. When finalized, they will provide a flexible and streamlined approach to the oversight of tests that detect medically important differences in a person’s...
2016-2017 Oncology Meetings
AUGUST Palliative Medicine and Supportive Oncology 2016August 3-6 • Cleveland, OhioFor more information:www.clevelandclinicmeded.com/live/courses/pallmed/default.asp 17th Annual International Lung Cancer Congress®August 4-6 • Huntington Beach, CaliforniaFor more information:...
Fred Hutchinson Cancer Research Center Appoints 2016–2017 Board Members, Including Microsoft CEO and Former Governor of Washington
Fred Hutchinson Cancer Research Center announced the appointment of Microsoft CEO Satya Nadella to its Board of Trustees. He is among five new board members at Fred Hutch, a Seattle-based pioneer in advancing groundbreaking research to prevent, diagnose, and treat cancer and related diseases. “I’m ...
Acupuncture: Does It Alleviate Symptoms Associated With Cancer Care?
A therapeutic modality of traditional Chinese medicine, acupuncture has been extensively investigated in Western medical settings. Its clinical use is increasingly common for the management of pain and other conditions. In the oncology setting, research demonstrates that acupuncture can...
Fentanyl Nasal Spray Now Available at a Dose of 300 µg for Treatment of Breakthrough Cancer Pain
Fentanyl (Lazanda) nasal spray, a schedule II narcotic, is now available at a 300-µg dose to treat breakthrough cancer pain, offering physicians another titration option for dosing flexibility. The new strength can help physicians more easily and accurately target the appropriate dose for patients, ...
Stanford Cancer Institute Designated NCI Comprehensive Cancer Center
The Stanford Cancer Institute has been designated a Comprehensive Cancer Center by the National Cancer Institute (NCI), a part of the National Institutes of Health. The designation is recognition of the Institute’s robust and integrated programs encompassing laboratory research, clinical care, and ...
New ASTRO Clinical Practice Statement Updates Treatment Standard for Rectal Cancer
The American Society for Radiation Oncology (ASTRO) recently issued a new clinical practice statement, “Appropriate Customization of Radiation Therapy for Stage II and III Rectal Cancer: An ASTRO Clinical Practice Statement Using the RAND/UCLA Appropriateness Method.” An executive...
Study Finds New Whole-Exome Sequencing Test Accurately Identifies Actionable Mutations
Exome Cancer Test v1.0 (EXaCT-1), a new whole-exome sequencing test developed by the Englander Institute for Precision Medicine at Weill Cornell Medicine, detected mutations that guide precision cancer treatment with over 95% accuracy, according to a study by Rennert et al published in Genomic ...
As Low-Dose CT Screening Moves Into the Clinic, Implementation Issues Move Up on the Agenda
Low-dose computed tomography (CT) screening for lung cancer in high-risk groups is moving into the clinic in the wake of its approval by the U.S. Centers for Medicaid & Medicare Services. That does not mean, however, the discussion is over. As low-dose CT moves from research to everyday...
Lung Cancer Screening: Beneficial for Certain Populations but Not Without Controversy
The National Cancer Policy Forum of the National Academies of Sciences took up the issue of lung cancer screening at its mid-June workshop. Greta Massetti, PhD, Associate Director for Science, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention (CDC), and chair of ...
Steven M. Horwitz, MD, on Sequencing New Agents in Relapsed Peripheral T-Cell Lymphoma
Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, reviews the data supporting current treatment approaches for T-cell lymphomas and discusses the specific subtype criteria used to individualize therapy.
Pap Smear Screenings May Help Prevent Cervical Cancer in Women Over 65
A new study from the University of Illinois confirms a link between Papanicolaou (Pap) smear screenings and a lower risk of developing cervical cancer in women over age 65. However, most American health guidelines discourage women in that age range from receiving screenings unless they have...
ASCO Guideline on Endocrine Therapy for Metastatic Breast Cancer: Reaffirming Principles for Making Treatment Decisions
The role of endocrine therapy for hormone receptor–positive metastatic breast cancer is well established, and clinicians are strongly encouraged to consider one of several therapeutic options for the majority of patients who present with metastatic disease. The recent ASCO guideline on this topic, ...
Five-Year Survival Data: Brentuximab Vedotin May Be Curative in Some Patients With Hodgkin Lymphoma
Five-year survival data published by Chen et al in Blood suggest that the targeted therapy brentuximab vedotin (Adcetris) may be curative in some patients with Hodgkin lymphoma whose disease has persisted despite receiving previous therapies. This multinational phase II study examined brentuximab...
Road to Successful Use of Real-World Evidence for Drug Development Is Long and Rocky
Friends of Cancer Research (Friends) has been a leader in the push for better and faster cancer drug development. Now it is tackling the use of real-world evidence in clinical trials. This is the report of a meeting on the subject that took place on June 16 in Washington, DC.1 Real-world evidence...
The Metastatic Breast Cancer Project: Direct-to-Patient Research Initiative
A nationwide project is enlisting patients with breast cancer to share their tumor samples and clinical information. Launched in October 2015, the Metastatic Breast Cancer (MBC) Project has enrolled more than 2,000 patients from all 50 states and is yielding information that will be shared with...
ASCO and MECC Sponsor International Palliative Care Workshop in Kazakhstan
ASCO recently collaborated with the Middle East Cancer Consortium (MECC) to provide a 3-day International Palliative Care Workshop in Kazakhstan for health-care professionals, advocates, and volunteers in the former capital of Almaty. Dilyara Kaidarova, MD, PhD, Director of the Almaty Oncology...
Sarah S. Donaldson, MD, FASCO, Honored With Inaugural Women Who Conquer Cancer Mentorship Award
Sarah S. Donaldson, MD, FASCO, of Stanford University School of Medicine and Lucile Packard Children’s Hospital, is the recipient of the Inaugural Women Who Conquer Cancer Mentorship Award. Throughout her decades-long career, Dr. Donaldson has mentored countless trainees and young oncologists,...
Quick Takes on Promising New Approaches to Treating Breast Cancer
At the 2016 ASCO Annual Meeting, researchers reported encouraging results for several new drugs and treatment strategies for breast cancer. The ASCO Post brings you brief summaries of a select few. Abemaciclib Trial The cyclin-dependent kinase 4/6 (CDK4/6) inhibitor abemaciclib produced responses...
American Cancer Society Endorses HPV Vaccine Recommendations From CDC ACIP
The American Cancer Society (ACS) has endorsed human papillomavirus (HPV) vaccination recommendations from the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP), the principal source of guidance on U.S. immunization policy. The ACS's...
Selected Hematology Abstracts From the 2016 ASCO Annual Meeting
Here are several abstracts selected from the proceedings of the 2016 ASCO Annual Meeting, focusing on clinical trials on therapeutics in different types of leukemia, multiple myeloma, follicular lymphoma, and central nervous system (CNS) lymphoma. For full details of these study abstracts, visit...
Expert Point of View: Patricia A. Ganz, MD & Gregory A. Masters, MD
“This is a tremendous advance. If we had a drug that could achieve these results we would rush to use it. This is also personalized medicine that alerts the health-care team when symptoms need addressing. And it is very important that using the app led to appropriate use of scans and tests, which...
App Triggers Earlier Detection of Relapse, May Help Improve Survival of Patients With Lung Cancer
Web-based applications have invaded mainstream culture and grabbed the attention of multitudes of people around the world. According to a study presented at the 2016 ASCO Annual Meeting, an app may also contribute to extending the lives of people with cancer and, at the same time, reduce...
Benefit Strongly Suggested With Hormonal Maintenance in Low-Grade Serous Carcinoma
In patients with low-grade serous carcinoma, maintenance hormonal therapy reduced the risk of recurrence by 77%, compared with surveillance, in a retrospective cohort from The University of Texas MD Anderson Cancer Center. The study was reported by David Marc Gershenson, MD, at the 2016 ASCO...
Expert Point of View: Marc S. Ernstoff, MD
The field of studies of combination immunotherapies is exploding, and “the future looks bright, with currently 71 trials of combination therapy in melanoma,” said formal discussant of these trials Marc S. Ernstoff, MD, of Roswell Park Cancer Institute, Buffalo, New York. “We now know that...
Studies Suggest Bright Future for Combination Immunotherapy in Advanced Melanoma, but Questions Remain
Two studies presented at the 2016 ASCO Annual Meeting focused on the use of combination immunotherapy in the treatment of patients with advanced melanoma. Updated results from the phase III CheckMate 067 trial centered on the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) compared...
CMS Proposal for Part B Drug Payment: A Poorly Conceived Experiment
On March 11, 2016, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule in the Federal Register to test a change in reimbursement for Part B drugs.1 The first phase involves changing the 6% add-on to the average sales price (ASP) used to make drug payments under Part B to...
Charting a New Course at the FDA
In February, after serving for a year as the U.S. Food and Drug Administration’s (FDA’s) Deputy Commissioner for Medical Products and Tobacco, Robert M. Califf, MD, MACC, was named the agency’s Commissioner of Food and Drugs. Prior to his appointment at the FDA, Dr. Califf was the Donald F....
Stress and Adverse Life Events Unlikely to Cause Breast Cancer
Day-to-day psychological stress and adverse life events are unlikely to increase a woman’s risk of developing breast cancer, according to a new prospective study published by Schoemaker et al in Breast Cancer Research. Women with breast cancer often consider stress as a likely cause of their ...
Early Evidence of Anti–PD-1 Activity in Enzalutamide-Resistant Prostate Cancer
Restoring tumor-specific immunity is a treatment strategy that works well in melanoma and lung cancer patients. Now a new study out of the Oregon Health & Science University (OSHU) Knight Cancer Institute is reviving hope that the approach also may help men with life-threatening prostate...
Early Results Find Pembrolizumab Active in Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
Findings in a classical Hodgkin lymphoma cohort in the phase Ib KEYNOTE-013 trial, reported by Armand et al in the Journal of Clinical Oncology, indicate that pembrolizumab (Keytruda) is active in patients with disease progressing on or after brentuximab vedotin (Adcetris) treatment. Study Details ...
Preclinical Study Shows Target of Trastuzumab, Receptor Protein ErbB2, Needed for Coronary Vasculature Patterning
A receptor protein that is the target of the breast cancer drug trastuzumab (Herceptin) is needed for proper heart blood vessel development, reported researchers from the Perelman School of Medicine at the University of Pennsylvania, Philadelphia. They published their findings this month in a paper ...
Weight Loss in Overweight and Obese People May Lower Levels of Certain Proteins Linked to Cancer
A new study investigating the effects of dietary weight loss and exercise on circulating levels of certain angiogenesis-related proteins, including vascular endothelial growth factor (VEGF), plasminogen activator inhibitor-1 (PAI-1), and pigment epithelium-derived factor (PEDF), in postmenopausal...
Opportunistic Salpingectomy for Ovarian Cancer Prevention Adopted Without Adverse Surgical Outcomes
A surgical procedure recommended to reduce the future risk of ovarian cancer has been successfully implemented throughout Kaiser Permanente in Northern California without a change in surgical outcomes, according to research published by Garcia et al in Obstetrics & Gynecology. Previous...
Internationally Renowned Geneticist, Alfred George Knudson, MD, PhD, Dies
Considered a visionary in cancer research, Alfred George Knudson, MD, PhD, was internationally recognized for his “two-hit theory” of cancer causation, which explained the relationship between hereditary and nonhereditary cancer types, predicting the existence of tumor-suppressor genes. ...
New Analysis Evaluates Predictors of Persistent Pain After Breast Cancer Surgery
An analysis led by McMaster University researchers has found that women who undergo armpit lymph node surgery for breast cancer are much more likely to develop chronic pain. Wang et al published their review of studies exploring risk factors for developing chronic pain after breast cancer...
Heart Failure After First Heart Attack Associated With Increased Risk of Cancer
Patients who develop heart failure after their first heart attack have a greater risk of developing cancer when compared to first-time heart attack survivors without heart failure, according to a study published by Hasin et al in the Journal of the American College of Cardiology. Heart failure...
